Skip to content

Evaluation of the Effectiveness of a Psychoeducational Intervention on Benzodiazepine Use in the Population Over 64 Years Old in Primary Care

Evaluation of the Effectiveness of a Psychoeducational Intervention on Benzodiazepine Use in the Population Over 64 Years Old in Primary Care

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06950567
Acronym
BENZOS-AP
Enrollment
122
Registered
2025-04-30
Start date
2024-04-01
Completion date
2025-10-15
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disminución Del Consumo Benzodiacepinas, suspensión Completa Del Tratamiento Con Benzodicepinas

Keywords

Deprescribing, Benzodiazepines, Primary Health Care, Patient Education, Benzodiazepine Withdrawal, Long-term Benzodiazepine Use

Brief summary

The goal of this pragmatic, multicenter, randomized controlled trial is to determine whether a multidisciplinary psychoeducational intervention combined with therapeutic exercise is more effective than a minimal educational intervention alone in helping older adults with long-term benzodiazepine use discontinue or reduce their medication. The main questions it aims to answer are: Does the multidisciplinary intervention increase the proportion of participants who completely discontinue benzodiazepine treatment? Does the intervention reduce the weekly benzodiazepine dose compared with the minimal intervention alone? Researchers compared a minimal educational intervention ("Benzocarta") with the same intervention plus an 8-week multidisciplinary psychoeducational program and supervised therapeutic exercise. Participants: received a personalized educational letter from their family physician explaining the risks of long-term benzodiazepine use and providing guidance for gradual dose reduction; were randomly assigned either to the control group (minimal intervention only) or to the intervention group (minimal intervention plus psychoeducational sessions and therapeutic exercise); were followed for 6 and 18 months after the initial intervention to assess benzodiazepine discontinuation and changes in weekly dose.

Detailed description

Long-term benzodiazepine use is common among older adults despite recommendations limiting treatment duration because of the increased risk of dependence, falls, cognitive impairment and other adverse effects. Although several interventions have been proposed to support benzodiazepine deprescribing, their implementation in routine primary care remains limited. This pragmatic, multicenter randomized controlled trial was designed to evaluate the effectiveness of a multidisciplinary intervention delivered in routine primary care. The intervention combined a minimal educational strategy consisting of a personalized letter from the participant's family physician ("Benzocarta") with an 8-week group-based psychoeducational program and supervised therapeutic exercise. The comparator group received the minimal educational intervention alone, reflecting usual clinical practice. The intervention was delivered by a multidisciplinary primary care team and focused on promoting benzodiazepine deprescribing through education, behavioural strategies and non-pharmacological management of insomnia, anxiety and stress. The study was conducted under real-world conditions in four primary care centres. Although the minimum required sample size was 69 participants, recruitment continued during the planned recruitment period because additional family physicians agreed to participate during the planned recruitment period. Consequently, the final enrolled sample exceeded the minimum target specified in the original protocol (122 participants). Follow-up assessments were performed at 6 and 18 months after the initial intervention to evaluate the long-term sustainability of benzodiazepine deprescribing and the occurrence of late relapse in benzodiazepine use. Protocol amendment: An additional follow-up assessment at 18 months after the initial intervention was incorporated before data analysis to evaluate the persistence of benzodiazepine discontinuation and potential late relapse. This amendment did not modify participant allocation, study interventions, or outcome definitions.

Interventions

OTHERpsycho-educational intervention and therapeutic activity

The objective is to provide knowledge and skills to tolerate/reduce discomfort so that they can begin to reduce or discontinue medication (BZD). The focus is on the effect of combined care, but the implementation of this approach is also evaluated, which will provide valuable knowledge for further health developments in Primary Care.

OTHERControl

Sending a "Benzocarta" to each person's postal address-a personalized letter signed by their Family Doctor, an explanatory sheet on how to gradually reduce medication, and infographics on sleep hygiene, stress, or anxiety.

Sponsors

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Lead SponsorOTHER
Fundacio d'Atencio Primaria
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This was a pragmatic, multicenter, parallel-group randomized controlled trial conducted in primary care. Eligible participants identified by family physicians were individually randomized in a 1:2 ratio (intervention:control). All participants received a minimal educational intervention ("Benzocarta"), consisting of a personalized letter signed by their family physician with information on the risks of long-term benzodiazepine use, gradual dose reduction, a tapering schedule, and advice on sleep hygiene and stress management. Participants in the intervention group additionally received an 8-week multidisciplinary psychoeducational program with supervised therapeutic exercise, whereas the control group received no further structured intervention. Outcomes were assessed at 6 and 18 months after the initial intervention.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥65 years. * Current benzodiazepine use for ≥3 months. * Ability to provide written informed consent.

Exclusion criteria

* Severe psychiatric disorder, dementia, or epilepsy. * Enrollment in a home care program, institutionalization, or palliative care. * Language barriers or mobility limitations preventing attendance at the primary care centre.

Design outcomes

Primary

MeasureTime frameDescription
Number of participants who completely discontinued benzodiazepine treatment6 and 18 months after the initial interventionComplete discontinuation of prescribed benzodiazepine treatment, defined as the absence of benzodiazepine use at follow-up, regardless of the baseline dose. The outcome was assessed by comparing the proportion of participants who had completely discontinued treatment in the intervention and control groups.

Secondary

MeasureTime frameDescription
Change in weekly benzodiazepine dose expressed as diazepam equivalents6 and 18 months after the initial interventionChange from baseline in the prescribed weekly benzodiazepine dose, expressed as diazepam-equivalent milligrams per week, comparing the intervention and control groups. Among participants who did not completely discontinue treatment, the proportions achieving partial dose reduction or maintaining the same dose were also described.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026